Influenza A virus vaccine H5N2 intranasal - BioDiem

Drug Profile

Influenza A virus vaccine H5N2 intranasal - BioDiem

Alternative Names: GPO Avian Flu Vaccine; GPO H5N2 PLAIV; Intranasal H5N2 vaccine - Institute of Experimental Medicine of the Russian Academy of Medical Sciences/Biodiem; LAIV H5N2 pandemic vaccine; LAIV H5N2/A/Len/17; Pandemic LAIV H5N2

Latest Information Update: 10 Mar 2016

Price : $50

At a glance

  • Originator Institute of Experimental Medicine of the Russian Academy of Medical Sciences
  • Developer Government Pharmaceutical Organization; Institute of Experimental Medicine of the Russian Academy of Medical Sciences; Mahidol University; World Health Organization
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 10 Mar 2016 Phase-II development in Influenza A virus H5N2 subtype is ongoing in Thailand (Intranasal)
  • 01 Jan 2013 Phase-II clinical trials in Influenza A virus H5N2 subtype in Thailand (Intranasal)
  • 01 May 2012 Phase-I clinical trials for Influenza A virus H5N2 subtype in Thailand (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top